SCHEMBL2895280

SCHEMBL2895280

Cc1ccc(F)c(-n2nnc(CO)n2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.40
GRIN1 Q05586 3/20 0.40
GRIN2B Q13224 3/20 0.40
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
LMNA P02545 1/20 0.36
NOTUM Q6P988 2/20 0.34
MAPK1 P28482 1/20 0.34
MAP2K4 P45985 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
MAPKAPK3 Q16644 1/20 0.34
MAPK6 Q16659 1/20 0.34
DHODH Q02127 3/20 0.34
KDM4E B2RXH2 3/20 0.33
FFAR4 Q5NUL3 1/20 0.33
KCNN4 O15554 1/20 0.32
TRPV1 Q8NER1 1/20 0.32
MGLL Q99685 1/20 0.32
SRC P12931 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5740464 0.90 RXRA (0.38) RXRAGRIN1GRIN2BNPC1RAB9A
SCHEMBL2892992 0.79 RXRA (0.39) RXRAGRIN1GRIN2BLMNAMAPK1
SCHEMBL27669088 0.77 KIF11 (0.39) GRIN2BLMNAMAPK1KDM4EFFAR4
SCHEMBL2889384 0.77 RXRA (0.36) RXRAGRIN1GRIN2BNPC1RAB9A
SCHEMBL2895031 0.75 RXRA (0.39) RXRAGRIN1GRIN2BNPC1RAB9A
SCHEMBL2893736 0.75 ALDH1A1 (0.50) LMNAMAPK1KDM4EALDH1A1TDP1
SCHEMBL5740390 0.74 LMNA (0.34) RXRAGRIN1GRIN2BNPC1RAB9A
SCHEMBL5739224 0.74 NOTUM (0.37) NOTUMKDM4EMAPT
SCHEMBL2897330 0.72 MAPT (0.39) RXRAGRIN1GRIN2BLMNAALDH1A1
SCHEMBL19211471 0.72 NOTUM (0.64) RXRAGRIN1GRIN2BNOTUMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1716125-B1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2013-06-19 EP disclosed
CN-1918137-B Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2012-08-01 CN disclosed
CN-101845023-A Tetrazole compound and as the application of metabotropic glutamate receptor antagonists NPS PHARMA INC 2010-09-29 CN disclosed
US-7691892-B2 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2010-04-06 US disclosed
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-23 US disclosed
CN-1918137-A Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-02-21 CN disclosed
EP-1716125-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS AstraZeneca AB (SE) 2006-11-02 EP disclosed
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-01-05 US disclosed
WO-2005080356-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 RXRA 349/4885GRIN1 9/4885GRIN2B 18/4885
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 RXRA 363/4885GRIN1 8/4885GRIN2B 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.